AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
49 hedge funds and large institutions have $141M invested in AVEO Pharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 14 closing their positions.
1,723% more call options, than puts
Call options by funds: $1.6M | Put options by funds: $88K
326% more capital invested
Capital invested by funds: $33.2M → $141M (+$108M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
0% more funds holding
Funds holding: 49 → 49 (0)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$6.64M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.36M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$2.12M |
| 4 |
Millennium Management
New York
|
+$1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$915K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$2.52M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$885K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$872K |
| 4 |
NLVP
New Leaf Venture Partners
New York
|
-$787K |
| 5 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$598K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
51
Sarissa Capital Management
Greenwich,
Connecticut
| – | -$598K | -101,362 | Closed |
|
|
SM
52
Sabby Management
Miami Beach,
Florida
| – | -$513K | -86,890 | Closed |
|
|
CAM
53
Cormorant Asset Management
Boston,
Massachusetts
| – | -$413K | -70,000 | Closed |
|
|
UOC
54
UBS O'Connor
Chicago,
Illinois
| – | -$291K | -49,360 | Closed |
|
55
Tudor Investment Corp
Stamford,
Connecticut
| – | -$49K | -8,387 | Closed |
|
56
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$42K | -7,140 | Closed |
|
|
VKH
57
Virtu KCG Holdings
New York
| – | -$27K | -4,622 | Closed |
|
58
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$11K | -1,850 | Closed |
|
59
LPL Financial
San Diego,
California
| – | -$9K | -1,400 | Closed |
|
|
CAG
60
Crestwood Advisors Group
Boston,
Massachusetts
| – | -$3K | -506 | Closed |
|
|
CG
61
Cutler Group
San Francisco,
California
| – | -$1K | -296 | Closed |
|
62
UBS Group
Zurich,
Switzerland
| – | -$882 | -112 | -92% |
|
63
Simplex Trading
Chicago,
Illinois
| – | -$598 | -76 | Closed |
|
AVEO Hedge Fund Activity: Q2 2017 in Review
49 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q2 2017, worth a combined $141M — up 326% from $33.2M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new AVEO positions and 14 closed out — a net gain of 1 holder — while 9 added to existing stakes and 10 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $6.64M. The largest seller was Armistice Capital, cutting an estimated $2.52M.
- 49 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $141M of AVEO Pharmaceuticals, Inc. stock for Q2 2017, up 326% quarter-over-quarter.
- 15 funds opened new AVEO Pharmaceuticals, Inc. positions in Q2 2017 and 14 closed out, a net change of +1 holder.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q2 2017 was RA Capital Management, an estimated $6.64M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q2 2017 was Armistice Capital, an estimated $2.52M sold.
Based on aggregated 13F filings for Q2 2017.